Angiotensin-converting enzyme inhibitors, but not angiotensin II receptor blockers, were associated with significant declines in the odds of all-cause mortality, cardiovascular deaths and major CV events in diabetes patients compared with placebo, a study indicated. "ACEIs should be considered as first-line therapy to limit excess mortality and morbidity in this population," researchers wrote in JAMA Internal Medicine.

Related Summaries